Menu

Anna Turkova, Clinical Principal Research Fellow

Anna Turkova is a research clinician at the MRC Clinical Trials Unit at UCL and a Consultant Paediatrician at the Great Ormond Street Hospital, London. 

She is a Chief Investigator of the D3 trial, a multi-country randomised controlled trial testing if children and young people living with HIV can take two anti-HIV medicines instead of three.

Anna is a study physician in several large international paediatric HIV and TB trials and observational multi-centre studies (e.g. ODYSSEY, SHINE, EPPICC). She is co-leading one of the work packages of the UNIVERSAL project, a European-African Project on new treatment formulations for children living with HIV.

Anna was a Scientific Coordinator of the Russian European Alliance for Research among Women and Children affected by HIV, TB and HCV (REACH). She has been working with the Penta ID network since 2011, and has been teaching on Penta training courses in Eastern and Western Europe, Central Asia and Africa.  

Anna is one of the authors of the EACS/Penta Guidelines for Treatment of Paediatric HIV. She is a co-chair of the WHO-led Paediatric Antiretroviral Working Group (PAWG), and a member of WHO HIV Guidelines Development Group, Paediatric Antiretroviral Drug Optimisation (PADO) group, Paediatric Working Group on Hepatitis (PWGH), the Child and Adolescent TB Working Group and the Global Accelerator for Paediatric Formulations Network (GAP-f). 


Selected publications

Turkova A, Wills GH, Wobudeya E, Chabala C, Palmer M, Kinikar A, Hissar S, Choo L, Musoke P, Mulenga V, Mave V, Joseph B, LeBeau K, Thomason MJ, Mboizi RB, Kapasa M, van der Zalm MM, Raichur P, Bhavani PK, McIlleron H, Demers AM, Aarnoutse R, Love-Koh J, Seddon JA, Welch SB, Graham SM, Hesseling AC, Gibb DM, Crook AM; SHINE Trial Team. Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children. N Engl J Med. 2022 Mar 10;386(10):911-922. doi: 10.1056/NEJMoa2104535

Turkova A, White E, Mujuru HA, Kekitiinwa AR, Kityo CM, Violari A, Lugemwa A, Cressey TR, Musoke P, Variava E, Cotton MF, Archary M, Puthanakit T, Behuhuma O, Kobbe R, Welch SB, Bwakura-Dangarembizi M, Amuge P, Kaudha E, Barlow-Mosha L, Makumbi S, Ramsagar N, Ngampiyaskul C, Musoro G, Atwine L, Liberty A, Musiime V, Bbuye D, Ahimbisibwe GM, Chalermpantmetagul S, Ali S, Sarfati T, Wynne B, Shakeshaft C, Colbers A, Klein N, Bernays S, Saïdi Y, Coelho A, Grossele T, Compagnucci A, Giaquinto C, Rojo P, Ford D, Gibb DM; ODYSSEY Trial Team. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. N Engl J Med. 2021 Dec 30;385(27):2531-2543. doi: 10.1056/NEJMoa2108793

Turkova A, Waalewijn H, Chan MK, Bollen PDJ, Bwakura-Dangarembizi MF, Kekitiinwa AR, Cotton MF, Lugemwa A, Variava E, Ahimbisibwe GM, Srirompotong U, Mumbiro V, Amuge P, Zuidewind P, Ali S, Kityo CM, Archary M, Ferrand RA, Violari A, Gibb DM, Burger DM, Ford D, Colbers A; ODYSSEY Trial Team. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. Lancet HIV. 2022 Sep;9(9):e627-e637. doi: 10.1016/S2352-3018(22)00160-6

Turkova A, White E, Kekitiinwa AR, Mumbiro V, Kaudha E, Liberty A, Ahimbisibwe GM, Moloantoa T, Srirompotong U, Mosia NR, Puthanakit T, Kobbe R, Fortuny C, Kataike H, Bbuye D, Na-Rajsima S, Coelho A, Lugemwa A, Bwakura-Dangarembizi MF, Klein N, Mujuru HA, Kityo C, Cotton MF, Ferrand RA, Giaquinto C, Rojo P, Violari A, Gibb DM, Ford D; ODYSSEY trial team. Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial. Lancet Child Adolesc Health. 2023 Aug 7:S2352-4642(23)00164-5. doi: 10.1016/S2352-4642(23)00164-5

Matthews PC, Ocama P, Wang S, El-Sayed M, Turkova A, Ford D, Torimiro J, Garcia Ferreira AC, Espinosa Miranda A, De La Hoz Restrepo FP, Seremba E, Mbu R, Pan CQ, Razavi H, Dusheiko G, Spearman CW, Hamid S. Enhancing interventions for prevention of mother-to-child- transmission of hepatitis B virus. JHEP Rep. 2023 Apr 24;5(8):100777. doi: 10.1016/j.jhepr.2023.100777

Turner RM, Turkova A, Moore CL, Bamford A, Archary M, Barlow-Mosha LN, Cotton MF, Cressey TR, Kaudha E, Lugemwa A, Lyall H, Mujuru HA, Mulenga V, Musiime V, Rojo P, Tudor-Williams G, Welch SB, Gibb DM, Ford D, White IR; the ODYSSEY Trial Team. Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial. BMC Med Res Methodol. 2022 Feb 20;22(1):49. doi: 10.1186/s12874-022-01539-3





Research Interests

  • Paediatric Infections
  • HIV
  • Tuberculosis
  • Hepatitis
  • Clinical Trials


Research Areas



UCL Profiles